Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Search results are limited to:
Abstract Book of the 7th European Myeloma Network Meeting, Prague, 16-18 April 2026
Vol. 111 No. s2
Showing matches for the individual search terms you entered. To search for an exact phrase, enclose your query in quotes.
Advanced filters
Search the full archive
Keyword matches

B02 | THE PROGNOSTIC IMPACT OF BONE MARROW PLASMA CELL INFILTRATION AT DIAGNOSIS IN AL AMYLOIDOSIS (341 Online Views)

K. Aslantaş1, Ş. Özlü2, I. Kuzu2, M. Beksaç3|4, G. Cengiz Seval4

1 Department of Internal Medicine, Ankara University Faculty of Medicine, Turkey
2 Department of Pathology, Ankara University Faculty of Medicine, Turkey
3 Istinye University, Ankara Liv Hospital, Turkey
4 Department of Hematology, Ankara University Faculty of Medicine, Turkey
AL amyloidosis BMPC Turkey

P71 | DARATUMUMAB IN PATIENTS WITH AL AMYLOIDOSIS: A PORTUGUESE MULTICENTER REAL-WORLD STUDY (235 Online Views)

R. Bergantim1, A. Roque2, J. Vieira3, G. Ferreira4, P. Martins Almeida3, P. Ferraz5, J. G. Freitas6, M. Neves7, E. Aguiar1, M. Lopes8, H. Martins3, F. Trigo1, C. Geraldes2, C. João7

1 ULS São João, Porto, Portugal
2 ULS Coimbra, Portugal
3 ULS Santa Maria, Lisboa, Portugal
4 ULS Aveiro, Portugal
5 ULS TMAD, Vila Real, Portugal
6 ULS Braga, Portugal
7 Fundação Champalimaud, Lisboa, Portugal
8 ULS EDV, Santa Maria da Feira, Portugal
AL amyloidosis Multiple Myeloma Real-world Study

P63 | TECLISTAMY (EMN40): A PHASE 2 TRIAL OF TECLISTAMAB IN PATIENTS WITH PREVIOUSLY TREATED LIGHT-CHAIN AL AMYLOIDOSIS (261 Online Views)

M. Roussel1, E. Kastritis2, S.O. Schönland3, K.M. Kortüm4, B. Arnulf5|6, A. Jaccard1, S. Vara7, M. Doyle7, J.M. Schecter7, A. Carpinteiro8, F. Kwok9, G. Palladini10|11, M.C. Minnema12, M. Boccadoro13, P. Sonneveld14|15

1 Hematology, Centre Hospitalier Universitaire Dupuytren, Limoges, France
2 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece
3 Department of Internal Medicine V, Heidelberg University Hospital, Germany
4 Department of Internal Medicine II, University Hospital of Würzburg, Germany
5 Immuno-Hematology, Saint Louis Hospital, AP-HP, Paris, France
6 Université Paris Cité, France
7 Johnson & Johnson
8 Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Germany
9 Department of Haematology, Westmead Hospital, Sydney, Australia
10 Department of Molecular Medicine, University of Pavia, Italy
11 Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
12 Department of Hematology, University Medical Center Utrecht, The Netherlands
13 European Myeloma Network, Italy
14 Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
15 European Myeloma Network, The Netherlands
AL amyloidosis TeclistAMY (EMN40) trial

P68 | BIOPSY SPECIFIC CHARACTERISTICS ARE IMPORTANT IN DETECTING AMYLOID IN PATIENTS WITH AMYLOIDOSIS (210 Online Views)

F.G. Weverling1, A. Vinkenborg1, R.J. Leguit2, M.C. Minnema1

1 Department of Hematology, University Medical Center Utrecht, The Netherlands
2 Department of Pathology, University Medical Center Utrecht, The Netherlands
AL amyloidosis Multiple Myeloma CR-staining

P70 | NOVEL MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE CARE PATHWAY FOR THE EARLY DETECTION OF M-PROTEIN RELATED DISEASES (202 Online Views)

M. Minnema1, F. Verheij1, J. Kortleve2, K. Aarsman1, R. Blommers2, R. Oostvogels1, P. Westerweel2

1 Department of Hematology, UMC Utrecht, The Netherlands
2 Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands
MGUS Al Amyloidosis Multiple Myeloma

P67 | TALQUETAMAB INDUCES DEEP RESPONSES IN HEAVILY PRE-TREATED PATIENTS WITH SYSTEMIC LIGHT-CHAIN AMYLOIDOSIS (246 Online Views)

T. Shragai1|2, M. Ganayem1, Y. Cohen1|2, I. Avivi1|2, E. Lebel3|4, N. Even-Gross Zohar3|4, N. Melamed1, M. Gatt3|4

1 Tel-Aviv Sourasky Medical Center, Israel
2 Tel-Aviv University, Israel
3 Hadassah Medical Center, Jerusalem, Israel
4 Hebrew University, Jerusalem, Israel
Multiple Myeloma AL amyloidosis Talquetamab

P72 | BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY AL AMYLOIDOSIS: CLINICAL EXPERIENCE IN TWO ACADEMIC BELGIAN CENTERS (202 Online Views)

M.C. Vekemans1, O. Rizzo2, N. Meuleman2

1 Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Bruxelles, Belgium
2 Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Belgium
AL Amyloidosis Multiple Myeloma anti-BCMA
Title matches

P75 | CURRENT STATUS OF REGISTRY OF MONOCLONAL GAMMOPATHIES - THE CZECH MYELOMA GROUP "REAL WORLD“ DATABASE (208 Online Views)

V. Maisnar1, L. Pour2, I. Spicka3, J. Minarik4, T. Jelinek5, A. Jungova6, P. Pavlicek7, L. Roziakova8, J. Radocha1, A. Heindorfer9, M. Sykora10, P. Kessler11, L. Stejskal12, M. Wrobel13, J. Kopeckova14, K. Stankova15, L. Pospisilova15, R. Hajek5

1 4th Department of Medicine - Hematology, University Hospital, Hradec Kralove, Czech Republic
2 Internal Hemato-Oncology Clinic, University Hospital, Brno, Czech Republic
3 1st Medical Department – Clinical Department of Haematology, General Teaching Hospital, Prague, Czech Republic
4 Department of Hematooncology, University Hospital, Olomouc, Czech Republic
5 Department of Clinical Hematology, University Hospital, Ostrava, Czech Republic
6 Department of Hemato-oncology, University Hospital, Plzen, Czech Republic
7 Department of Clinical Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic
8 Department of Clinical Hematology, University Hospital, Bratislava, Slovakia
9 Department of Hematology, Regional Hospital, Liberec, Czech Republic
10 Department of Clinical Hematology, Regional Hospital, Ceske Budejovice, Czech Republic
11 Department of Hematology, Regional Hospital, Pelhrimov, Czech Republic
12 Department of Hematology and Transfusion, Silesian Regional Hospital, Opava, Czech Republic
13 Department of Oncology, Regional Hospital, Novy Jicin, Czech Republic
14 Czech Myeloma Group, Brno, Czech Republic
15 Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
Real-world Practice Monoclonal Gammopathies RMG Working Group

P38 | SAFETY AND EFFICACY OF TALQUETAMAB + TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM PHASE 1b OF RedirecTT-1: RESULTS WITH AN EXTENDED MEDIAN FOLLOW-UP OF 3 YEARS (232 Online Views)

E.M. Ocio1|2, M-V. Mateos3, H. Magen4, M. Gatt5, M. Sebag6, K. Kim7, C-K. Min8, S-S. Yoon9, M.P. Chu10, P. Rodríguez-Otero11, I. Avivi4, N.A. Quijano Cardé12, M. Krevvata12, T. Henninger12, P. Thakkar12, M. Festa12, L. Huang12, J.X. Zhou12, M. Takamoto12, L. Pei12, J. Lu12, C. Maffucci12, E. Scott12, A. Oriol13, D. Morillo14, Y.C. Cohen4

1 Hospital Universitario Marqués de Valdecilla, Santander, Spain
2 Universidad de Cantabria, Santander, Spain
3 University Hospital of Salamanca, Spain
4 Tel Aviv University, Israel
5 Hebrew University of Jerusalem, Israel
6 McGill University, Montreal, Canada
7 Sungkyunkwan University School of Medicine, Seoul, Korea
8 The Catholic University of Korea, Seoul, Korea
9 Seoul National University College of Medicine, Korea
10 Alberta Health Services, Edmonton, Canada
11 Cancer Center Clínica Universidad de Navarra, Pamplona, Spain
12 Johnson & Johnson
13 Hospital Germans Trias i Pujol, Badalona, Spain
14 University Hospital Fundación Jiménez Díaz, Madrid, Spain
RRMM RedirecTT-1 Follow-up

P37 | ANALYSIS OF PATIENTS WITH PRIOR BCMA-TARGETED THERAPY AND THOSE ACHIEVING COMPLETE RESPONSE IN REALiTAL: A MULTI-COUNTRY OBSERVATIONAL STUDY OF TALQUETAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS (299 Online Views)

R. Popat1, K.M. Kortüm2, H. Magen3, V. Mykytiv4, C. Liberatore5, E. Zamagni6, M.C. Da Vià7, E. Antonioli8, M. Hansson9, D. Santra10, D. Greer10, K. Subrt11, P. Hu11, E. Aeby11, N. Francella11, N.M. Suñe11, A. Perrot12, K. Uttervall13

1 University College London Hospitals NHS Foundation Trust, UK
2 University Hospital of Würzburg, Germany
3 Tel Aviv University, Israel
4 Cork University Hospital, Ireland
5 Ospedale Santo Spirito, Pescara, Italy
6 University of Bologna, Italy
7 IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
8 Careggi Hospital and University of Florence, Italy
9 Sahlgrenska University Hospital, Gothenburg, Sweden
10 Parexel International
11 Johnson & Johnson
12 Université de Toulouse, France
13 Karolinska University Hospital, Stockholm, Sweden
Multiple Myeloma REALiTAL Trial RRMM

P39 | RANDOMIZED PHASE II DOSE OPTIMIZATION STUDY OF INOBRODIB (CCS1477) IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (243 Online Views)

E. Searle1, V. Campbell2, C. Pawlyn3, D. Vogl4, S. Holstein5, S. Gooding6, M. Jenner7, T. Creasey8, A. Chaidos9, P. Rodríguez-Otero10, F. Al-Kaisi11, A. Brearton12, S. Moore6, J. O’Nions13, T. Somervaille1, T. Knurowski14, K. Clegg14, S. Paul14, K. Frese14, N. Joseph15

1 The Christie NHS Foundation Trust, Manchester, UK
2 Western General Hospital, Edinburgh, UK
3 The Royal Marsden NHS Foundation Trust, London, UK
4 Hospital of the University of Pennsylvania, Philadelphia, USA
5 University of Nebraska Medical Center, Omaha, USA
6 Oxford University Hospitals NHS Foundation Trust, Oxford, UK
7 University Hospital Southampton NHS Foundation Trust, UK
8 Northern Centre for Cancer Care, Newcastle upon Tyne, UK
9 Imperial College Healthcare NHS Trust, London, UK
10 Clínica Universidad de Navarra, Pamplona, Spain
11 Royal Derby Hospital, UK
12 The Clatterbridge Cancer Centre, Liverpool, UK
13 University College London Hospital, UK
14 CellCentric Ltd, Cambridge, UK
15 Emory Winship Cancer Institute, Atlanta, USA
Multiple Myeloma Inobrodib RRMM

P53 | NATIONWIDE EXPERIENCE WITH STANDARD OF CARE IDECABTAGENE VICLEUCEL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL WORLD STUDY ON BEHALF OF THE GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO FOUNDATION (182 Online Views)

M. Puppi1|2|3, M. Pennisi4, F. Monaco5, L. Paris6, S. Aquino7, F. Ciceri8, M.C. Goldaniga9, M. Musso10, G. Buda11, M. Martino12, P. Chiusolo13, F. Fazio14, R. Mina15, F. Patriarca16, M.C. Tisi17, P. Tacchetti1, V. Marasco4, F. Ardizzoia1|2|3, M. Talarico1|2|3, K. Mancuso1|2|3, E. Maffini1, C. Carniti4, C. Terragna1, E. Zamagni1|2|3, F. Bonifazi1, M. Cavo2|3, P. Corradini4

1 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Italy
2 Department of Medical and Surgical Sciences
3 (DIMEC), University of Bologna, Italy
4 Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, University of Milan, Italy
5 AOSS Antonio e Biagio e Cesare Arrigo-SC Ematologia, Alessandria, Italy
6 ASST Papa Giovanni XXIII, Bergamo – SC Ematologia, Italy
7 Ematologia e Terapie cellulari, IRCCS Ospedale Policlinico San Martino, Genova, Italy
8 Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy
9 Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
10 Dipartimento Oncologico "La Maddalena", UOC di Oncoematologia e TMO, Palermo, Italy
11 Hematology Division, Pisa University Hospital, Department of Clinical and Experimental Medicine, University of Pisa, Italy
12 Stem Cell Transplantation and Cellular Therapies Unit, Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
13 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
14 Department of Translational and Precision Medicine, Hematology Azienda Policlinico Umberto I Sapienza University of Rome, Italy
15 AOU Città della Salute e della Scienza di Torino and the Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy
16 Clinica Ematologica ed Unità di Terapie Cellulari, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
17 Hematology Unit, San Bortolo Hospital, Vicenza, Italy
RRMM GIMEMA CAR-T

P40 | EFFICACY AND SAFETY OF TALQUETAMAB + TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND EXTRAMEDULLARY DISEASE: UPDATED PHASE 2 RESULTS FROM THE RedirecTT-1 STUDY WITH EXTENDED FOLLOW-UP (291 Online Views)

M.V. Mateos1, P. Rodríguez-Otero2, S.Z. Usmani3, S. Kumar4, J.C. Ye5, S. Atrash6, H. Magen7, H. Quach8, M.P. Chu9, S. Trudel10, J. Richter11, H. Chuah12, M. Gatt13, E. Medvedova14, S. Raza15, D.H. Yoon16, T. Ishida17, J.V. Matous18, L. Rosiñol19, K. Onodera20, C. Maffucci21, E. Scott21, C. Heuck21, J. Zhang21, T. Henninger21, L. O’Rourke21, P. Thakkar21, M. Festa21, L. Huang21, J. Zhou21, M. Takamoto21, L. Pei21, J. Lu21, N. Au21, M. Krevvata21, Y.C. Cohen7

1 University Hospital of Salamanca, Spain
2 Cancer Center Clínica Universidad de Navarra, Pamplona, Spain
3 Memorial Sloan Kettering Cancer Center, New York, USA
4 Mayo Clinic Rochester, USA
5 University of Texas, Houston, USA
6 Levine Cancer Institute-Atrium Health, Charlotte, USA
7 Tel Aviv University, Israel
8 University of Melbourne, Australia
9 Alberta Health Services, Edmonton, Canada
10 Princess Margaret Cancer Centre, Toronto, Canada
11 Mount Sinai Medical Center, New York, USA
12 Royal Perth Hospital, Australia
13 Hebrew University of Jerusalem, Israel
14 Oregon Health and Science University, Portland, USA
15 Cleveland Clinic, USA
16 University of Ulsan College of Medicine, Seoul, Korea
17 Japanese Red Cross Medical Center, Tokyo, Japan
18 Colorado Blood Cancer Institute, Denver, USA
19 Hospital Clínic de Barcelona, Spain
20 Tohoku University Hospital, Sendai, Japan
21 Johnson & Johnson
Multiple Myeloma RedirecTT-1 trial RRMM

P41 | FIRST RESULTS OF REALiTEC-2: SECOND COHORT OF REALiTEC, AN INTERNATIONAL OBSERVATIONAL RETROSPECTIVE STUDY OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN ROUTINE CLINICAL PRACTICE (244 Online Views)

R. Popat1, K. Uttervall2, K.M. Kortüm3, H. Magen4, M. Hansson5, T. Shragai6, E. Terpos7, C. T. Hansen8, S. Manier9|10, H. Gregersen11, Ø.M. Ottestad12, C. Touzeau13, E. Hatjiharissi14|15, S.L. Farmer16, E. Katodritou17, E. Spanoudakis18, M.Ø. Vase19, C. Liberatore20|21, M. Papathanasiou22, M.K. Angelopoulou7|23, E. Clavero24, R. Kittus25, P. Smirnov25, P. Hu25, D. Santra26, C. Albrecht25, E. Rubio-Azpeitia25, A. Perrot27

1 University College London Hospitals NHS Foundation Trust, UK
2 Karolinska University Hospital, Stockholm, Sweden
3 University Hospital of Würzburg, Germany
4 Tel-Aviv University, Israel
5 Sahlgrenska University Hospital, Gothenburg, Sweden
6 Tel-Aviv Sourasky Medical Center, Israel
7 National and Kapodistrian University of Athens, Greece
8 Odense University Hospital, Denmark
9 University of Lille, France
10 Centre Hospitalier Universitaire Lille, France
11 Aalborg University Hospital, Denmark
12 Akershus University Hospital, Lørenskog, Norway
13 University Hospital Hôtel-Dieu, Nantes, France
14 AHEPA University Hospital, Thessaloniki, Greece
15 Aristotle University of Thessaloniki, Greece
16 Vejle Hospital, Denmark
17 Theagenio Cancer Hospital, Thessaloniki, Greece
18 Democritus University of Thrace, Alexandroupolis, Greece
19 Aarhus University Hospital, Denmark
20 Santo Spirito Hospital, Pescara, Italy
21 "G d'Annunzio" University, Chieti, Italy
22 G Papanicolaou Hospital, Thessaloniki, Greece
23 Laiko General Hospital, Athens, Greece
24 Hospital Universitario Virgen De Las Nieves, Granada, Spain
25 Johnson and Johnson
26 Parexel International on behalf of Johnson & Johnson, Sheffield, UK
27 Université de Toulouse, France
REALiTEC-2 Trial RRMM Teclistamab

P36 | EFFECTIVENESS OF BRIDGING THERAPY CORRESPONDS TO IMPROVED OUTCOMES AFTER CILTACABTAGENE AUTOLEUCEL: PHASE 3 CARTITUDE-4 STUDY OF PATIENTS WITH RELAPSED, LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA (281 Online Views)

E. Zamagni1, B. Dhakal2, S. Iida3, M.H. Sidiqi4|5, S.S. Yoon6, N. Callander7, C. Touzeau8|9|10|11, Q. Li12, A. Balogh12, A. Slaughter12, N. Benachour12, C. Lonardi12, A. Ghosh12, M. Vogel12, N. Lendvai12, T. Lengil12, M. Koneru13, N. Patel13, O. Costa Filho13, V. Mahajan13, J. Martínez-López14, K. Yong15, K. Weisel16, X. Leleu17

1 University of Bologna, Italy
2 Medical College of Wisconsin, Milwaukee, USA
3 Nagoya City University, Japan
4 Fiona Stanley Hospital, Perth, Australia
5 Curtin University, Perth, Australia
6 Seoul National University, Korea
7 University of Wisconsin, Madison, USA
8 Centre Hospitalier Universitaire Hotel Dieu, Nantes, France
9 Université d’Angers, Nantes, France
10 Université de Nantes, France
11 French Ministry of Health, Nantes, France
12 Johnson & Johnson
13 Legend Biotech USA Inc, Somerset, USA
14 Complutense University, Madrid, Spain
15 University College London, UK
16 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
17 CHU Poitiers, France
Multiple Myeloma CARTITUDE-4

P42 | COMPARATIVE EFFECTIVENESS OF TECLISTAMAB IN REALiTEC VS. REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN LOCOMMOTION AND MOMMENT IN TRIPLE-CLASS EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA (198 Online Views)

A. Perrot1, M. Kortüm2, R. Popat3, K. Uttervall4, M.V. Mateos5, K. Weisel6, K. Van Nimwegen7, J. Diels7, F. Ong7, R. Morano7, E. Rubio-Azpeitia7, P. Moreau8

1 Universite de Toulouse, France
2 University Hospital of Würzburg, Germany
3 University College London Hospitals NHS Foundation Trust, UK
4 Karolinska University Hospital, Stockholm, Sweden
5 Hospital Universitario de Salamanca, Spain
6 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
7 Johnson & Johnson
8 University Hospital Hôtel-Dieu, Nantes, France
Multiple Myeloma RRMM Teclistamab

P44 | EARLIER USE OF CILTACABTAGENE AUTOLEUCEL IS ASSOCIATED WITH BETTER IMMUNE FITNESS AND STRONGER IMMUNE EFFECTS AS SHOWN BY CORRELATIVE ANALYSIS OF PERIPHERAL BLOOD AND THE BONE MARROW TUMOR MICROENVIRONMENT FROM THE CARTITUDE-4 STUDY (280 Online Views)

N.W.C.J. Van De Donk1, S. Parekh2, K. Li3, Y. Lin4, T.G. Martin5, S. Han2, R. Montes De Oca2, M. Suraneni3, M. Gormley2, B. Hodkinson2, J. Yuan2, F. Wang3, A. Kumar2, D. Yin2, D. Smirnov2, J. Patel2, N. Lendvai3, D. Madduri3, J. Zhu6, M. Koneru6, N. Patel6, D. Geng6, V. Plaks2, S. Harrison7|8|9

1 Vrije Universiteit Amsterdam, The Netherlands
2 Icahn School of Medicine at Mount Sinai, New York, USA
3 Johnson & Johnson
4 Mayo Clinic, Rochester, USA
5 University of California San Francisco, USA
6 Legend Biotech USA Inc, Somerset, USA
7 Peter MacCallum Cancer Centre, Melbourne, Australia
8 Royal Melbourne Hospital, Australia
9 University of Melbourne, Parkville, Australia
CARTITUDE-4 Prognostic Biomarkers RRMM

P45 | MODELING DORMANCY IN MULTIPLE MYELOMA: FUNCTIONAL AND TRANSCRIPTOMIC CHARACTERIZATION OF SERUM STARVATION AND CHEMOTHERAPY-INDUCED STATES (216 Online Views)

Z.S. Najafabadi1, N. Afrin2, M. Helal2, H. Fischer1, M. John2, E. Stanojkovska1, J. Mersi1, S. Kadel1, J. Waldschmidt1, M. Kortüm1, K. Kretzschmar2, H. Einsele1, A. Riedel2, L. Rasche1|2

1 Internal Medicine II, Universitätsklinikum Würzburg, Germany
2 Mildred Scheel Early Career Centre for Cancer Research Würzburg, The Julius-Maximilians-Universität Würzburg, Germany
Multiple Myeloma Cancer cell dormancy 3D Model

P47 | UTILITY AND SENSITIVITY OF WETT-SA53 TO MEASURE DYSGEUSIA ASSOCIATED WITH TALQUETAMAB, A GPRC5D×CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY DATA FROM THE TALISMAN STUDY (265 Online Views)

R. Popat1, N.W.C.J. Van De Donk2|3, B. Faiman4, J. Yuda5, K. Kim6, A. Costa7, A. Laheij2|3, R.L. Doty8, J. Omel9, B. Lipe10, L. Sanchez11, A. Chari12, A. Lin13, H. Sroussi14, M. Fernandez15, K.S. Gray15, G. Aguilar15, K. Bolyard15, J. Schultz15, K. Qi15, D. Cortes-Selva15, J. Zhang15, C. Heuck15, K. Hawks15, K. Tian15, M. França15, L. Rasche16

1 University College London Hospitals NHS Foundation Trust, UK
2 Amsterdam University Medical Center, The Netherlands
3 Vrije Universiteit Amsterdam, The Netherlands
4 Cleveland Clinic, USA
5 National Cancer Center Hospital East, Kashiwa, Japan
6 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
7 D’or Institute for Research and Education, São Paulo, Brazil
8 University of Pennsylvania Smell and Taste Center, Philadelphia, USA
9 The Central Nebraska Myeloma Support Group, Grand Island, USA
10 University of Rochester Medical Center, USA
11 Icahn School of Medicine at Mount Sinai, New York, USA
12 University of California, San Francisco, USA
13 University of Pennsylvania, Philadelphia, USA
14 Brigham and Women’s Hospital, and Harvard School of Dental Medicine, Boston, USA
15 Johnson & Johnson
16 University Hospital of Würzburg, Germany
TALISMAN study Multiple Myeloma RRMM

P48 | LONG-TERM PROGRESSION-FREE SURVIVAL BENEFIT WITH CILTACABTAGENE AUTOLEUCEL IN STANDARD-RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA (259 Online Views)

D. Dytfeld1, L.J. Costa2, A. Oriol3, S. Manier4|5, P.M. Voorhees6, Y. Lin7, M. Htut8, W. Roeloffzen9, P. J. Ho10|11, U. Shah12|13, M. Zhao14, Q. Li15, A. Balogh15, K. Li15, A. Slaughter15, N. Benachour15, C. Lonardi15, A. Ghosh15, H. Sun15, N. Lendvai15, T. Lengil15, N. Patel16, M. Koneru16, E. Florendo16, O. C. Filho16, V. Mahajan16, P. Rodríguez-Otero17, C. Strouse18, A.K. Stewart19|20, S. Sidana21

1 Poznan University of Medical Sciences, Poznań, Poland
2 University of Alabama at Birmingham, USA
3 Hospital Germans Trias i Pujol, Barcelona, Spain
4 University of Lille, France
5 Centre Hospitalier Universitaire Lille, France
6 Wake Forest University, Charlotte, USA
7 Mayo Clinic, Rochester, USA
8 City of Hope Comprehensive Cancer Center, Duarte, USA
9 University Medical Center Groningen, The Netherlands
10 Royal Prince Alfred Hospital, Sydney, Australia
11 The University of Sydney, Australia
12 Memorial Sloan Kettering Cancer Center, New York, USA
13 Weill Cornell Medical College, New York, USA
14 IQVIA, Shangai, China
15 Johnson & Johnson
16 Legend Biotech USA Inc, Somerset, USA
17 Universidad de Navarra, Pamplona, Spain
18 University of Iowa, Iowa City, USA
19 University Health Network, Toronto, Canada
20 The Princess Margaret Cancer Centre, Toronto, Canada
21 Stanford University, USA
CARTITUDE-4 Multiple Myeloma Progression free

P50 | INPATIENT VS. OUTPATIENT TREATMENT MANAGEMENT WITH TECLISTAMAB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A COST AND HEALTHCARE RESOURCE UTILIZATION ANALYSIS (239 Online Views)

N.W.C.J. Van De Donk1, R. Wester2, I. Nijhof3, C. Albrecht4, R. Morano5, C. Entrala6, K. Van Nimwegen1|2|3|4|5|6

1 Amsterdam University Medical Center, The Netherlands
2 Erasmus Medical Center, Rotterdam, The Netherlands
3 St. Antonius Ziekenhuis, Nieuwegein, The Netherlands
4 Johnson & Johnson, Paris, France
5 Johnson & Johnson, Madrid, Spain
6 Johnson & Johnson, Breda, The Netherlands
Multiple Myeloma RRMM Treatment Management

P51 | EVOLVING ATTRITION RATES IN MULTIPLE MYELOMA REAL-WORLD PRACTICE OVER A 30-YEARS PERIOD FROM A SINGLE CENTER EXPERIENCE (219 Online Views)

G. Giunta1, C. Bellofiore2, E. Scalisi1, F. Elia2|1, B. Garibaldi2, C. Finocchiaro1, F. Di Raimondo2|1, A. Romano2|1, C. Conticello2

1 Postgraduate School of Hematology, University of Catania, Italy
2 Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, Italy

B01 | TIME-RESOLVED MULTI-LAYERED PROFILING IDENTIFIES RESOLUTION OF RIBOSOME COLLISIONS AND TRANSLATIONAL RECOVERY AS MECHANISMS CONTRIBUTING TO PROTEASOME INHIBITOR RESISTANCE (399 Online Views)

J. Zhou1, N.T. Crump1, M. Román-Trufero1|2, H.W. Auner1|2|3

1 Department of Immunology and Inflammation, Imperial College London, UK
2 Division of Haematology and Central Haematology Laboratory, Lausanne University Hospital, Switzerland
3 Faculty of Biology and Medicine, University of Lausanne, Switzerland
Proteasome Inhibitor Resistance Carfilzomib Multiple Myeloma

P54 | EVOLVING OUTCOMES IN MULTIPLE MYELOMA REAL-WORLD PRACTICE: 30-YEARS SINGLE CENTER EXPERIENCE (175 Online Views)

G. Giunta1, C. Bellofiore2, E. Scalisi1, V. Del Fabro3, F. Elia1|2, B. Garibaldi2, C. Finocchiaro1, F. Di Raimondo1|2, A. Romano1|2, C. Conticello2

1 Postgraduate School of Hematology, University of Catania, Italy
2 Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, Italy
3 Faculty of Medicine and Surgery, “Kore” University of Enna, Italy
Multiple myeloma Real-World Practice Sicily

P55 | MANAGEMENT OF NEUROLOGICAL TOXICITIES OF PATIENTS TREATED WITH IMMUNOTHERAPIES FOR MULTIPLE MYELOMA: A SINGLE-CENTER REAL WORLD EXPERIENCE (212 Online Views)

E. Manzato1|2, M. Puppi1|2, M. Talarico1|2, M. Iezza1|2, S. Masci1|2, S. Ghibellini1|2, A. Vitale2, S. Barbato1|2, P. Tacchetti1, L. Pantani1, K. Mancuso1|2, E. Zamagni1|2

1 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia L. A. Seràgnoli, Italy
2 Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Italy
Multiple Myeloma Neurological Toxicities RRMM
1 - 25 of 82 items 1 2 3 4 > >> 
Navigate
For Authors
For Reviewers
For Advertisers
Education
Privacy
More
Copyright © 2026 by the Ferrata Storti Foundation | Web design ￫ | Development ￫
ISSN 0390-6078 print | ISSN 1592-8721 online